EyePoint Pharmaceuticals Inc. (PV3B)
XDUS 
Summary
PV3B Chart
EyePoint: Sell-Off As Duravyu Fails Head-To-Head Study Vs Eylea May Be Overblown
Eyepoint Pharmaceuticals (EYPT) plunged ~70% after its LUGANO Phase 3 trial for Duravyu in wet AMD failed the primary endpoint due to an anomalous cohort. EYPT's management argues the failure was driven by nine patients (4%) with vision loss unrelated to wet AMD, and highlights strong secondary endpoints and durability advantages. Upcoming LUCIA Phase 3 data in Q4 2026 is pivotal; a positive result could revive the Duravyu program and restore investor confidence.
EYPT Stock Plunges 67% After Duravyu Misses Phase III Eye Disease Goal
EyePoint's Duravyu misses the phase III wet AMD study's primary goal, sending shares down 67%, but shows lower treatment burden and durable disease control.
EyePoint (EYPT) Reports Q2 Loss, Beats Revenue Estimates
EyePoint (EYPT) came out with a quarterly loss of $1.09 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to a loss of $0.85 per share a year ago.
EyePoint Pharmaceuticals Inc. (PV3B) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has EyePoint Pharmaceuticals Inc. ever had a stock split?
EyePoint Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jay S. Duker CEO | XDUS Exchange | US30233G2093 ISIN |
| US Country | 214 Employees | - Last Dividend | 11 Jun 2008 Last Split | 27 Jan 2005 IPO Date |
Overview
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for patients suffering from serious retinal diseases. Utilizing its proprietary bioerodible Durasert E technology, the company endeavors to offer sustained intraocular drug delivery solutions. Originating as pSivida Corp. before rebranding to EyePoint Pharmaceuticals in March 2018, the company has been advancing its mission since its inception in 1987. Headquartered in Watertown, Massachusetts, EyePoint Pharmaceuticals is committed to leveraging its technological innovations to address the unmet medical needs of patients with retinal disorders.
Products and Services
-
EYP-1901
This lead product candidate represents a significant advancement in the treatment of VEGF-mediated retinal diseases. EYP-1901 combines vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with EyePoint's Durasert E technology for sustained delivery. Currently, it is in Phase 2 clinical trials targeting conditions such as wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). This investigational treatment underscores the company's commitment to addressing the complexities of retinal diseases through innovative sustained delivery mechanisms.
-
EYP-2301
Another promising pipeline program, EYP-2301, harnesses the Durasert E technology to formulate a TIE-2 agonist. This approach is aimed at improving outcomes in serious retinal diseases by potentially offering a novel mechanism of action. While still under development, EYP-2301 exemplifies EyePoint Pharmaceuticals' ongoing exploration of diverse therapeutic avenues to meet the varied challenges posed by retinal diseases.
